Dow Jones

39 164,06

0,09%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NYSE
Bausch Health Companies Inc (BHC)
Bausch Health Companies Inc (BHC) Actualités

BHC

Bausch Health Companies (BHC)

Bausch Health Companies Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NYSE:BHC

1 2 3 4 5 6 7 8 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
06/06/2024	23h18	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:BHC	Bausch Health Companies Inc
21/05/2024	22h09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:BHC	Bausch Health Companies Inc
21/05/2024	22h01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:BHC	Bausch Health Companies Inc
15/05/2024	14h07	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHC	Bausch Health Companies Inc
04/03/2024	16h36	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:BHC	Bausch Health Companies Inc
22/02/2024	23h04	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NYSE:BHC	Bausch Health Companies Inc
13/02/2024	22h30	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NYSE:BHC	Bausch Health Companies Inc
08/02/2024	03h00	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NYSE:BHC	Bausch Health Companies Inc
13/11/2023	22h50	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NYSE:BHC	Bausch Health Companies Inc
02/11/2023	21h58	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:BHC	Bausch Health Companies Inc
21/10/2023	00h05	Dow Jones News	Bausch Health Gets FDA Approval for Acne Treatment Cabtreo	NYSE:BHC	Bausch Health Companies Inc
26/09/2023	11h45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Bausch Health Companies Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 25, 2023 - (NYSE: BHC)	NYSE:BHC	Bausch Health Companies Inc
03/08/2023	23h25	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NYSE:BHC	Bausch Health Companies Inc
26/07/2023	11h45	PR Newswire (US)	INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Bausch Health Companies Inc. of an Investigation and Potential Class Action Lawsuit - (NYSE: BHC)	NYSE:BHC	Bausch Health Companies Inc
21/07/2023	11h45	PR Newswire (US)	BHC FRAUD ALERT: Jakubowitz Law is Investigating Bausch Health Companies Inc. in Connection with Potential Violations of Federal Securities Laws	NYSE:BHC	Bausch Health Companies Inc
19/07/2023	22h02	Edgar (US Regulatory)	Form SD - Specialized disclosure report	NYSE:BHC	Bausch Health Companies Inc
06/06/2023	17h30	Dow Jones News	Bausch Health Shares Drop After Norwich Sues FDA for Final OK for Rival Drug	NYSE:BHC	Bausch Health Companies Inc
31/05/2023	14h00	PR Newswire (US)	OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease	NYSE:BHC	Bausch Health Companies Inc
19/05/2023	22h28	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:BHC	Bausch Health Companies Inc
17/05/2023	14h17	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:BHC	Bausch Health Companies Inc
03/05/2023	12h58	PR Newswire (Canada)	RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada	NYSE:BHC	Bausch Health Companies Inc
03/05/2023	12h58	PR Newswire (Canada)	RYALTRIS(MD), une nouvelle association sous ordonnance en pulvérisateur nasal pour la rhinite allergique saisonnière (RAS) d'intensité modérée à grave, est maintenant disponible partout au Canada	NYSE:BHC	Bausch Health Companies Inc
06/04/2023	22h50	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NYSE:BHC	Bausch Health Companies Inc
06/04/2023	22h48	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NYSE:BHC	Bausch Health Companies Inc
06/04/2023	22h47	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NYSE:BHC	Bausch Health Companies Inc
06/03/2023	19h33	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NYSE:BHC	Bausch Health Companies Inc
23/02/2023	23h31	Edgar (US Regulatory)	Annual Report (10-k)	NYSE:BHC	Bausch Health Companies Inc
14/02/2023	16h41	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NYSE:BHC	Bausch Health Companies Inc
22/12/2022	12h59	PR Newswire (Canada)	First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans	NYSE:BHC	Bausch Health Companies Inc
22/12/2022	12h59	PR Newswire (Canada)	ARAZLOMC (lotion de tazarotène, 0,045 %), la première lotion à base de tazarotène indiquée pour le traitement de l'acné vulgaire, est maintenant offerte aux patients du Québec, de l'Ontario, de l'Alberta et de la Saskatchewan dans le cadre des régi	NYSE:BHC	Bausch Health Companies Inc